Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CIS-565C improves glucose metabolism with fewer CNS side effects in mouse models of obesity

June 11, 2009

AS-1907417 shows preclinical potential for the treatment of type 2 diabetes

June 11, 2009

CHMP recommends granting of marketing authorization for Orphan Europe's Vedrop

June 11, 2009

BioMarin reports results from phase I PEG-PAL in phenylketonuria

June 11, 2009

Pfizer describes prostaglandin EP2 antagonists for the treatment of endometriosis

June 10, 2009

Kuros completes recruitment in phase IIb Kur-111 trial in tibial plateau fractures

June 9, 2009

FDA accepts for review Dyax's complete response submission for DX-88 in HAE

June 9, 2009

Shionogi presents NPY Y5 receptor antagonists for the treatment of obesity

June 9, 2009

Pharming receives EMEA agreement on pediatric investigation plan for Rhucin

June 8, 2009

AstraZeneca and Abbott submit NDA for Certriad for mixed dyslipidemia

June 5, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.